It is worrisome that it took 30 years to realize statins increase diabetes says two cardiologists
Thursday, June 02, 2016 2:54 pm Email this article
“As for the safety of statin treatment – a major issue for medical doctors – it is quite worrisome to realize that it took 30 years to bring to light the triggering effect of statins on new-onset diabetes, manifestly reflecting a high level of bias in reporting harmful outcomes in commercial trials, as has been admitted by the recent confession of prominent experts in statin treatment,” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.
Obviously, the drug companies hid this information and their paid researchers went along with this lie.
Can you understand why I don’t believe anything from the drug companies or from their paid researchers?
They Looked At Statin Trials Published Since 2005/2006
They looked at studies published since 2005/2006 because “Around the years 2005/2006, new stricter Regulations were introduced in the conduct and publication of randomized controlled trials” they noted.
I No Longer Believe ANY Drug Company-Sponsored Studies
I no longer believe ANY study sponsored by the drug companies or ANY papers written by people paid by the drug companies as I noted in 2014.
The drug companies have been caught lying too many times.
de Lorgeril M, and Rabaeus M. Beyond Confusion and Controversy, Can We Evaluate the Real Efficacy and Safety of Cholesterol-Lowering with Statins? Journal of Controversies in Biomedical Research, 2015; 1(1): 67-92. http://jcbmr.com/index.php/jcbmr/article/view/11/26.
Author’s Contact Info
Michel de Lorgeril, MD
TIMC-IMAG CNRS UMR 5525
Laboratoire Cœur et Nutrition
Université Joseph Fourier
About Michel de Lorgeril, MD
Researchgate.net notes that:
“Michel de Lorgeril is a cardiologist and nutritionist at the French National Centre for Scientific Research and the School of Medicine at Grenoble University, France.
“In the 1990s he proposed a theory to explain the French paradox (low mortality rate from cardiac disease in France compared with UK and USA despite similar risk profiles), and his research group demonstrated that the plant omega-3 fatty acid (alpha-linolenic acid) is cardioprotective.
“Michel de Lorgeril was the principal investigator on the landmark Lyon Diet Heart Study, the first clinical trial to demonstrate the beneficial effects of the Mediterranean diet in the prevention of ischemic heart disease.”